Enabling Healthier Lungs
by Deton Corp. on July 20th, 2017

​Deton Corp. has been awarded a $225,000 National Institute of Health (NIH) Small Business Innovation Research (SBIR) contract. The award will fund a clinical study to investigate the advantages of using the Deton Cough Collector for pediatric Cystic Fibrosis patients with lower respiratory infections.

by Deton Corp. on March 22nd, 2017

​Most Promising Company at the 2017 Molecular Medicine Tri-Conference
​On February 22, 2017, Deton CEO and Co-Founder Patrick Sislian, PhD took 1st place at the 2017 Molecular Medicine Tri-Conference “Swimming with the Sharks” competition in San Francisco.  Deton was chosen as the Most Promising Company by a panel of judges consisting of venture capitalists, angels, and diagnostic industry executives. The judges noted that Deton had a well thought out go-to-market strategy, a unique solution addressed a large unmet clinical need, and a clear ask.  “We at Deton are incredibly excited and grateful for this diagnostic industry award,” said Sislian. “The future of medicine is increasingly evidence-based and our win shows the the Cough Collector is well positioned to enable lower respiratory disease diagnosis.”

Deton presented as one of the 8 finalists selected from numerous applicants to this year’s competition from across molecular medicine, including drug discovery, genomics, diagnostics and information technology.  The other finalists were: Abreos Biosciences, Envision Genomics, Nephrogen Sciences, Selfdiagnostics, Geneoscopy, PrecisionProfile, SpinDiag. 
About Molecular Medicine Tri-Conference
Attracting over 3,500 drug discovery and development professionals from over 40 countries in 2016, the Molecular Medicine Tri-Conference has grown into a diverse event, focusing on Molecular Medicine, specifically on Discovery, Genomics, Diagnostics and Information Technology.  This conference features over 500 speakers from across all industries and research fields across the world as well as over 400 presentations and panel discussions, 30 roundtable discussions and over 200 companies exhibiting.  Back by popular demand is the "Swimming with the Sharks" competition.  Companies seeking venture funding will pitch their company's value proposition to a panel of judges and the top place winner will receive recognition as the "2017 Tri-Con Most Promising Company".

About Deton
Deton is promoting lung health by enabling diagnosis of disease through the collection, management, and analysis of cough aerosols. Deton’s solution, the Cough Collector, will make diagnosing lower respiratory infections easy, rapid and reliable, paving the way for targeted treatments and better patient outcomes. Armed with the evidence, doctors will be able to prescribe antibiotics empowered with reliable information. Deton is headquartered in Pasadena, California (Los Angeles). For more information, please visit www.detoncorp.com 

by Deton Corp. on October 1st, 2016

Deton has been selected by the National Institutes of Health to be featured at the AdvaMed2016 Innovation Showcase in Minneapolis. As part of the Infectious Disease Management panel, Patrick Sislian will share his insights on the challenges of lower respiratory infection diagnostics and the effective collection of samples through aerosols produced by cough.  The moderated panel will take place on October 17 at 4:40pm. 

by Deton Corp. on August 18th, 2016

​Deton was selected, as one of seven medical device companies, to participate in the Innovation Challenge at the 10th RESI Conference in Boston on September 13, 2016. If you are attending, swing by our booth to meet our CEO, Patrick Sislian, and our CSO, David Aloisi, and learn more about the Cough Collector, a device that will make diagnosing lower respiratory infections easy and reliable.

by Deton Corp. on August 4th, 2016

​LOS ANGELES – August 4, 2016 – Deton Corp., a medical device company developing innovative products for the diagnosis of lower respiratory infections, has secured $600,000 in an oversubscribed seed financing round. The round was led by a venture fund based in Shanghai and included angel investor participation. “The seed financing comes at a pivotal time for the company, as we accelerate our ongoing efforts in product and market development,” said Patrick Sislian, Ph.D., CEO of Deton Corp. “This financing gets us closer to our goal of becoming the world-leaders in non-invasive sample collection from the lower respiratory tract.”

Deton’s product, the Cough Collector, addresses long standing challenges in the diagnosis of lower respiratory infections.  “The Cough Collector is a great leap building on existing methods for sampling and diagnosis of lower respiratory infections that are dated and often ineffective,” said Antonino Catanzaro, M.D., Chair of Deton’s Medical Advisory Board and Professor of Medicine at the University of California, San Diego. “Deton’s method of sampling aerosols generated by coughing to produce a reliable sample is simple, non-invasive and effective and will lead to faster and more effective treatment of these infections.”

Deton is a participant in the Consortium for Technology and Innovation in Pediatrics (CTIP), a pediatric technology accelerator operated by the Center for Innovation at Children’s Hospital Los Angeles. “We are excited about Deton’s technology and its potential to dramatically improve pediatric patients’ lives,” said Jessica Rousset, Co-Director of CTIP. “We look forward to working more closely with Deton to help bring their product to market.”

About Children's Hospital Los Angeles (CHLA), Center for Innovation (CFI), Consortium for Technology and Innovation in Pediatrics (CTIP)
Children's Hospital Los Angeles has been named the best children’s hospital in California and among the top 10 in the nation for clinical excellence with its selection to the prestigious U.S. News & World Report Honor Roll. The Center for Innovation at CHLA raises standards of pediatric care by bringing together clinicians, scientists, engineers, patients and industry leaders to develop, commercialize and implement new devices and medicines specifically for babies and children.  With seed funding from the U.S. Food and Drug Administration (FDA), the CFI oversees the Consortium for Technology and Innovation in Pediatrics (CTIP), an accelerator which engages innovators dedicated to developing unique technology solutions that help pediatric patients. For more information, please visit www.scctip.com.

About Deton Corp.
Deton Corp. is creating products that effectively obtain samples from the lower respiratory tract with a focus on diagnosing infections. Deton’s device non-invasively collects and concentrates cough droplets - the same ones that transmit infections - from the lungs. The result is a concentrated, clean, and easy-to-process sample enabling rapid test results that empower doctors to appropriately prescribe targeted antibiotic therapies when necessary and avoid ineffective treatments that can lead to antibiotic resistance. Deton is headquartered in Pasadena, California (Los Angeles). For more information, please visit www.detoncorp.com

Patrick Sislian